72 related articles for article (PubMed ID: 16357142)
21. Embryonic stem cell microenvironment suppresses the malignancy of cutaneous melanoma cells by down-regulating PI3K/AKT pathway.
Wang C; Wang X; Liu J; Huang Z; Li C; Liu Y; Sang X; Yang L; Wang S; Su Y; Liu C; Liu Y; Wang Z
Cancer Med; 2019 Aug; 8(9):4265-4277. PubMed ID: 31173492
[TBL] [Abstract][Full Text] [Related]
22. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.
Qie S; Yoshida A; Parnham S; Oleinik N; Beeson GC; Beeson CC; Ogretmen B; Bass AJ; Wong KK; Rustgi AK; Diehl JA
Nat Commun; 2019 Mar; 10(1):1296. PubMed ID: 30899002
[TBL] [Abstract][Full Text] [Related]
23. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest.
Goel S; DeCristo MJ; McAllister SS; Zhao JJ
Trends Cell Biol; 2018 Nov; 28(11):911-925. PubMed ID: 30061045
[TBL] [Abstract][Full Text] [Related]
24. Untapped Reserves: Controlling Primordial Follicle Growth Activation.
Kallen A; Polotsky AJ; Johnson J
Trends Mol Med; 2018 Mar; 24(3):319-331. PubMed ID: 29452791
[TBL] [Abstract][Full Text] [Related]
25.
Tarrado-Castellarnau M; de Atauri P; Tarragó-Celada J; Perarnau J; Yuneva M; Thomson TM; Cascante M
Mol Syst Biol; 2017 Oct; 13(10):940. PubMed ID: 28978620
[TBL] [Abstract][Full Text] [Related]
26. [Effect of TSC2 gene expression downregulation by lentivirus induced RNA interference on U937 cell line and its mechanism].
Xu ZF; Liu HX; Tan YH; Chen XH; Ren FG; Zhang YF; Chang JM; Zhang N; Hu JJ; Wang HW
Zhonghua Xue Ye Xue Za Zhi; 2017 Jul; 38(7):612-617. PubMed ID: 28810331
[No Abstract] [Full Text] [Related]
27. Coupling TOR to the Cell Cycle by the Greatwall-Endosulfine-PP2A-B55 Pathway.
Pérez-Hidalgo L; Moreno S
Biomolecules; 2017 Aug; 7(3):. PubMed ID: 28777780
[TBL] [Abstract][Full Text] [Related]
28. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.
Pikman Y; Alexe G; Roti G; Conway AS; Furman A; Lee ES; Place AE; Kim S; Saran C; Modiste R; Weinstock DM; Harris M; Kung AL; Silverman LB; Stegmaier K
Clin Cancer Res; 2017 Feb; 23(4):1012-1024. PubMed ID: 28151717
[No Abstract] [Full Text] [Related]
29. CDK4/6 inhibition: the late harvest cycle begins.
Goel S; Zhao JJ
Oncotarget; 2016 Aug; 7(31):48854-48856. PubMed ID: 27391058
[No Abstract] [Full Text] [Related]
30. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.
Goel S; Wang Q; Watt AC; Tolaney SM; Dillon DA; Li W; Ramm S; Palmer AC; Yuzugullu H; Varadan V; Tuck D; Harris LN; Wong KK; Liu XS; Sicinski P; Winer EP; Krop IE; Zhao JJ
Cancer Cell; 2016 Mar; 29(3):255-269. PubMed ID: 26977878
[TBL] [Abstract][Full Text] [Related]
31. CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.
Tigan AS; Bellutti F; Kollmann K; Tebb G; Sexl V
Oncogene; 2016 Jun; 35(24):3083-91. PubMed ID: 26500059
[TBL] [Abstract][Full Text] [Related]
32. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.
Heilmann AM; Perera RM; Ecker V; Nicolay BN; Bardeesy N; Benes CH; Dyson NJ
Cancer Res; 2014 Jul; 74(14):3947-58. PubMed ID: 24986516
[TBL] [Abstract][Full Text] [Related]
33. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis.
Kollmann K; Heller G; Schneckenleithner C; Warsch W; Scheicher R; Ott RG; Schäfer M; Fajmann S; Schlederer M; Schiefer AI; Reichart U; Mayerhofer M; Hoeller C; Zöchbauer-Müller S; Kerjaschki D; Bock C; Kenner L; Hoefler G; Freissmuth M; Green AR; Moriggl R; Busslinger M; Malumbres M; Sexl V
Cancer Cell; 2013 Aug; 24(2):167-81. PubMed ID: 23948297
[TBL] [Abstract][Full Text] [Related]
34. MEK drives cyclin D1 hyperelevation during geroconversion.
Leontieva OV; Demidenko ZN; Blagosklonny MV
Cell Death Differ; 2013 Sep; 20(9):1241-9. PubMed ID: 23852369
[TBL] [Abstract][Full Text] [Related]
35. Identification of new cell size control genes in S. cerevisiae.
Dungrawala H; Hua H; Wright J; Abraham L; Kasemsri T; McDowell A; Stilwell J; Schneider BL
Cell Div; 2012 Dec; 7(1):24. PubMed ID: 23234503
[TBL] [Abstract][Full Text] [Related]
36. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells.
Leontieva OV; Lenzo F; Demidenko ZN; Blagosklonny MV
Cell Cycle; 2012 Dec; 11(24):4642-9. PubMed ID: 23187803
[TBL] [Abstract][Full Text] [Related]
37. Cyclin D as a therapeutic target in cancer.
Musgrove EA; Caldon CE; Barraclough J; Stone A; Sutherland RL
Nat Rev Cancer; 2011 Jul; 11(8):558-72. PubMed ID: 21734724
[TBL] [Abstract][Full Text] [Related]
38. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.
Missiaglia E; Dalai I; Barbi S; Beghelli S; Falconi M; della Peruta M; Piemonti L; Capurso G; Di Florio A; delle Fave G; Pederzoli P; Croce CM; Scarpa A
J Clin Oncol; 2010 Jan; 28(2):245-55. PubMed ID: 19917848
[TBL] [Abstract][Full Text] [Related]
39. PKR, the double stranded RNA-dependent protein kinase as a critical target in Alzheimer's disease.
Morel M; Couturier J; Lafay-Chebassier C; Paccalin M; Page G
J Cell Mol Med; 2009 Aug; 13(8A):1476-88. PubMed ID: 19602051
[TBL] [Abstract][Full Text] [Related]
40. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.
Huang J; Manning BD
Biochem J; 2008 Jun; 412(2):179-90. PubMed ID: 18466115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
